TT 02332
Alternative Names: TT-02332Latest Information Update: 11 Mar 2024
At a glance
- Originator TransThera Biosciences
- Class Anti-inflammatories; Cardiovascular therapies; Obesity therapies; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Neurodegenerative disorders; Obesity